Formulation And Evaluation of Curcumin Gel Along With Ultrasound and Eccentric Exercises On Patellar Tendinopathy Management

The primary study aim of this study is to investigate the efficacy of an integrative treatment approach combining eccentric exercises with curcumin-enhanced ultrasound therapy for the management of knee tendinopathy.

Pragmatic, community based, parallel group, double blinded, randomised controlled trial. Total 90 patients will be enrolled. Patients who met our inclusion criteria randomised into two groups. Control group-A and treatment group-B

At Muhammad Institute of Medical and Allied Sciences Multan after getting approval from institutional ethical committee

Inclusion criteria: Participants between 18 to 60 years of age; patellar tendinopathy, confirmed by a qualified healthcare professional; chronic patellar tendinopathy symptoms for at least 3 months; moderate severity of symptoms; no active inflammatory conditions. Exclusion criteria: Individuals with acute (less than 3 months) patellar tendinopathy or other acute knee injuries; Participants with other significant knee conditions (e.g., patellofemoral pain syndrome, osteoarthritis, ligament injuries, or meniscal tears) that may confound the outcomes or interact with the treatments being tested; surgical interventions involving the patellar tendon or knee in the past 6 months; Individuals with uncontrolled systemic diseases, including rheumatoid arthritis, diabetes mellitus, or severe cardiovascular or neurological conditions that could affect tendon healing or physical activity.

Control group: Curcumin-aloe vera gel + ultrasound + eccentric exercises. Intervention group: Placebo aloe vera gel + ultrasound + eccentric exercises.

Pain, Knee ROM, Muscle strength ,Tendon thickness , Quality of life ,CRP, ESR and Tendon function

The randomization process will be conducted using computer-generated random numbers to assign participants to treatment groups in a predefined allocation sequence. A stratified or block randomization approach will be used to ensure balance between groups for key variables (e.g., age, gender, baseline disease severity). Medications will be prepared and packaged in identical numbered white boxes according to the allocation sequence. Each box will have a unique medication number corresponding to the assigned treatment, ensuring blinding. The allocation sequence and treatment codes will be securely stored and accessible only to the principal investigator, who is not involved in participant interactions or outcome assessments.

The statistical analyst and outcome assessor will be blinded to treatment allocation by using securely stored randomization codes, accessible only to an independent party. Data will be analyzed using anonymous identifiers, and group allocation will be revealed only after data collection and analysis are complete. This ensures minimization of bias.